MENU
Efficacy - Introduction
Efficacy - Chelation at Essential Sites
Efficacy - Dose-Dependent Chelation
Efficacy - Long-Term Efficacy
Efficacy - 24-Hour Activity
Efficacy - Clinical Trial Summaries
Safety - Long-Term Safety Profile
Safety - Side Effect Management
Safety - Monitoring Guidelines
Safety - Important Safety Information
Dosing - Dosing Guidelines
Dosing - Dose Calculator
Dosing - Serum Ferritin Tracker
Patient Types - Introduction
Patient Types - beta-Thalassemia
Patient Types - Myelodysplastic Syndromes
Patient Types - Sickle Cell Disease
Patient Types - Other Anemias
Patient Types - IPSS Calculator
Compliance Support - Introduction
Compliance Support - Side Effect Management
Compliance Support - Educational Tools
Exjade Resources - Summary of Resources and Tools
Exjade Resources - Related Links
Exjade Resources - Mechanism of Action
About Iron Toxicity - Iron Toxicity
About Iron Toxicity - Morbidity and Mortality
About Iron Toxicity - Screening and Monitoring
About Iron Toxicity - Managing Iron Toxicity
Exjade FAQs
About Novartis Oncology
Contact Us
Site Map
Terms of Use
Privacy Policy
Country Sites - Canada
Country Sites - Germany
Country Sites - Japan
Country Sites - Netherlands
Country Sites - Switzerland
Country Sites - United States
Swiss PI
EU SmPC
Novartis Oncology
Pubmed
Are You An Exjade Prescriber Seeking Tips For Treatment Success?
Are You Considering Exjade And Seeking Compelling Data?
Are You A Researcher Seeking Exjade Information Resources?
Exjade Important Safety Information
EXJADE is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in adult and pediatric patients (aged 2 years and over). Please click here for Swiss Prescribing Information. Please click here for EU SmPC. Please click here for Exjade Important Safety Information.
References: 1. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107(9):3455-3462. 2. Eleftheriou P, Tanner M, Pennel D, Porter JB. Response of myocardial T2* to oral deferasirox monotherapy for 1 year in 29 patients with transfusion-dependent anaemias; a subgroup analysis [11th Congress of the European Hematology Association abstract 0999]. Haematologica. 2006;91(s1):366. 3. Wood J, Thompson AA, Paley C, et al. ExjadeŽ reduces cardiac iron burden in chronically transfused beta-thalassemia patients: an MRI T2* study [American Society of Hematology 49th Annual Meeting abstract 2781]. Blood. 2007;110(11):817a. 4. EXJADE Swiss prescribing information. Berne, Switzerland: Novartis Pharma Schweiz Inc; 2008.
Disclaimer: This is an international website for EXJADE, and is intended for healthcare professionals outside the U.S. If you are a U.S. resident, please click on the U.S. residents link at the top of this page. The information on this site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located.
Š 2008 Novartis AG. Use of this website is subject to our Terms of Use.
The long-term efficacy of EXJADE has been studied in iron-overloaded patients with a wide range of underlying anemias, including ß-thalassemia, myelodysplastic syndromes (MDS), sickle cell disease (SCD), and other chronic anemias.
In pooled data from extensions of 4 core trials, benefits with EXJADE continued after a median of 3.4 years of treatment. Doses of 20 mg/kg/day maintained serum ferritin levels, and doses of 30 mg/kg/day delivered sustained reductions in serum ferritin.1
Dosing was adjusted as needed during the study, based on specified efficacy and safety markers.1
View EXJADE dosing guidelines.
View EXJADE long-term safety and tolerability profile.
Reference: 1. Porter JB, Cohen AR, Ford JM, Cappellini MD. Impact of dose adjustments on serum ferritin (SF) levels during long-term treatment with once-daily, oral deferasirox (ExjadeŽ, ICL670) [American Society of Hematology 49th Annual Meeting abstract 2778]. Blood. 2007;110(11):816a.
